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Special Report
Ultrafiltration Rate Thresholds in Maintenance Hemodialysis:
An NKF-KDOQI Controversies Report
Holly Kramer, MD, MPH,1,2 Jerry Yee, MD,3 Daniel E. Weiner, MD, MS,4
Vinod Bansal, MD,1 Michael J. Choi, MD,5 Laura Brereton, MSc,6 Jeffrey S. Berns, MD,7
Milagros Samaniego-Picota, MD,8 Paul Scheel Jr, MD, MBA,5 and Michael Rocco, MD 9
High hemodialysis ultrafiltration rate (UFR) is increasingly recognized as an important and modifiable risk
factor for mortality among patients receiving maintenance hemodialysis. Recently, the Kidney Care Quality
Alliance (KCQA) developed a UFR measure to assess dialysis unit care quality. The UFR measure was
defined as UFR $ 13 mL/kg/h for patients with dialysis session length less than 240 minutes and was
endorsed by the National Quality Forum as a quality measure in December 2015. Despite this, implementation
of a UFR threshold remains controversial. In this NKF-KDOQI (National Kidney Foundation2Kidney Disease
Outcomes Quality Initiative) Controversies Report, we discuss the concept of the UFR, which is governed by
patients’ interdialytic weight gain, body weight, and dialysis treatment time. We also examine the potential
benefits and pitfalls of adopting a UFR threshold as a clinical performance measure and outline several aspects of UFR thresholds that require further research.
Am J Kidney Dis. 68(4):522-532. ª 2016 by the National Kidney Foundation, Inc.
INDEX WORDS: Hemodialysis (HD); dialysis; ultrafiltration rate (UFR); quality of care; performance measure;
interdialytic weight gain (IDW); sodium; volume management; dialysis dose; treatment time; fluid removal; endstage renal disease (ESRD); NKF-KDOQI; controversies.

I

n 1995, the National Kidney Foundation (NKF)
launched the Dialysis Outcomes Quality Initiative
(DOQI) to improve outcomes for patients with endstage renal disease receiving maintenance dialysis,
resulting in the publication of clinical practice
guidelines that addressed dialysis treatment adequacy
in 1997.1 Twenty years and 2 guideline updates later,
many of the clinical questions posed in the guidelines
remain unanswered. To date, only 2 large-scale randomized clinical trials have assessed the effect of
different hemodialysis doses on clinical outcomes:
the National Cooperative Dialysis Study (NCDS)2
and the Hemodialysis (HEMO) Study,3 published
approximately 35 and 14 years ago, respectively.
Notably, participants in these trials are not representative of the current US hemodialysis population; the
NCDS excluded patients with diabetes, whereas the
HEMO Study generally excluded obese patients.

Consequently, much of the updated 2015 NKFKDOQI (NKF2Kidney Disease Outcomes Quality
Initiative) guideline for optimizing dialysis therapy
represents suggestions based on the clinical experiences of the writing group, anecdote grounded in
physiology, and lower-level data.4
Throughout the past decade, high hemodialysis
ultraﬁltration rates (UFRs) have been increasingly
recognized as an important and modiﬁable risk factor
for morbidity and mortality among patients receiving
maintenance hemodialysis, but to date, no clinical
trial has assessed clinical outcomes associated with a
given UFR limitation. Recently, both the Kidney Care
Quality Alliance (KCQA) and the Centers for Medicare & Medicaid Services (CMS) developed similar
measures addressing UFR in hemodialysis patients.
The KCQA metric development process used a
modiﬁed Delphi survey of stakeholders across the
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dialysis community to determine what aspect of
dialysis care should be targeted for measure development and identiﬁed volume management as the
area of greatest need. There are modest differences
between the KCQA and CMS measures, with the
measure stewarded by KCQA receiving National
Quality Forum endorsement in November 2015 (see
Table 1). Although the CMS-stewarded measure was
included in the 2016 calendar year End-Stage Renal
Disease Quality Incentive Program proposed rule,
CMS did not include a UFR reporting or performance
measure in the 2016 Final Rule.
Although widely acknowledged as important,
developing a UFR measure with a speciﬁc target is not
without controversy. For example, in a recent survey
administered by NKF-KDOQI on their website
(https://www.kidney.org/professionals/guidelines),
54% of 1,090 respondents answered “No” to the
following question: “Should hemodialysis units limit
ultraﬁltration rates for chronic dialysis patients
to ,10 ml/kg/hr?” In this NKF-KDOQI Controversies
Report, we review the history of dialysis treatment
time, one of the main components that deﬁne the UFR,
and discuss the existing controversies regarding the
potential implementation of UFR as a clinical performance measure. We also identify areas of research in
which clinical evidence is urgently needed to guide
clinical decision making regarding UFR limitations.

ULTRAFILTRATION RATE
The UFR is determined by the predialysis weight
and the desired postdialysis weight and is a function
of the total ﬂuid removed and the time devoted to
removing that ﬂuid, adjusted for patient weight. When
ultraﬁltration is performed, volume is removed from
the vascular space. Maintenance of effective circulating volume therefore depends on the ability of ﬂuid
from the interstitial space to reﬁll the vascular space;
this reﬁll varies from patient to patient.5 If ﬂuid is
removed too rapidly, patients may have symptomatic
intradialytic hypotension and/or cramping, both of
which may cause patients to terminate the dialysis
session prematurely.1 In extreme cases, patients may
have loss of consciousness. To treat intradialytic hypotension, patients may receive isotonic or hypertonic
saline solution; this ﬂuid bolus then impedes the
ability to reach the prescribed ultraﬁltration goal and
postdialysis “dry weight.” Recurrent episodes of
intradialytic hypotension are associated with higher
rates of hospitalizations and mortality.6 Excessive
interdialytic weight gain (IDWG), independent of
UFR, is recognized as an important predictor of
morbidity and mortality, and methods for mitigating
ﬂuid intake between treatments have been discussed
in all NKF-KDOQI dialysis guidelines.1,4,7,8 High
IDWG may lead to volume overload and clinical

Table 1. Description of the KCQA and CMS Measures for UFR Limits

Numerator

Denominator

Calculation period

Denominator exclusions

KCQA Measure

CMS Measure

No. of patients from denominator with average
UFR $ 13 mL/kg/h who receive an average
of ,240 minutes per treatment session during
calculation perioda
No. of adult in-center HD patients at reporting
facility undergoing maintenance HD during
calculation period
The same week the monthly Kt/V is drawn; the
annual performance on the metric is mean of
performance scores for each month over
performance year
(1) Patients aged , 18 y; (2) home dialysis patients;
(3) patients in a facility ,30 d; 4) patients with $4
HD treatment sessions during calculation period;
(5) patients with ,7 HD sessions in facility during
reporting month; (6) patients without a completed
CMS Medical Evidence Form in reporting month;
(7) kidney transplant recipients with functioning
transplant; (8) facilities treating #25 adult incenter HD patients during reporting month

No. of patient-months for adult ESRD patients at a
dialysis facility with UFR . 13 mL/kg/h

No. of adult in-center HD patients at reporting
facility undergoing maintenance HD during
calculation period
The last HD session of the month; the annual
performance on the metric is number of months
with UFR above threshold divided by total facility
patient-month
(1) Pediatric patients; (2) peritoneal dialysis
patients; (3) patients new to ESRD (,90 d on
maintenance dialysis); (4) patients who have not
been with same facility for entire reporting month
(transient patients)

Note: UFR is defined as total amount of fluid removed for a given dialysis session divided by dialysis session length and by the
patient’s body weight in kilograms.
Abbreviations: CMS, Centers for Medicare & Medicaid Services; ESRD, end-stage renal disease; HD, hemodialysis; KCQA, Kidney
Care Quality Alliance; UFR, ultrafiltration rate.
a
If more than 1 Kt/V is drawn in a given month, the last draw for the month will be used to define the data collection period (ie, these
data elements will be collected during the week that the final Kt/V value of the month is drawn).
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symptoms of volume overload if ﬂuid is not removed
in a timely fashion. If no changes are made in the
frequency or duration of dialysis sessions, high
IDWG will require a high UFR during a given hemodialysis session. For example, IDWG of 3.5 L in a
60-kg patient removed over a 4-hour dialysis session
results in a UFR of 14.6 mL/kg/h. Thus, the UFR and
IDWG are interdependent.

HISTORICAL CONTEXT OF DIALYSIS TREATMENT
TIME DETERMINATION
Dialysis treatment time is a critical factor in
determining the rate of ﬂuid removal, but has varied
dramatically over the history of dialysis. In the 1960s,
patients generally dialyzed once a week after the onset
of uremia.9 During the ensuing decade, dialysis time
gradually lengthened from 12 hours per session twice
weekly to more than 20 hours per session twice
weekly, with the goal of controlling hypertension and
reducing the progression of peripheral neuropathy. In
the early 1970s, the nephrology community suggested
that patients weighing at least 60 kg required a minimum of 18 hours per week of dialysis using coil
dialyzers and that dialysis thrice weekly led to less
neuropathy.9,10 Of note, these practices were based
entirely upon observation, anecdote, and opinion,
with no clinical trial data to support them.
The conﬂict between dialysis treatment time and
efﬁciency was examined in the NCDS. The NCDS
evaluated the effect of both dialysis treatment time
and efﬁciency, deﬁned by small-molecule clearance,
using a 2 3 2 factorial randomized trial design in 151
participants with 12 months’ planned follow-up. A
total of 151 patients from 9 dialysis units were
randomly assigned to 2 average urea concentration
arms (achieved by varying dialyzer sizes and ﬂow
rates) and either 3-times-per-week short (2.5-3.5
hours) or long (4.5-5 hours) dialysis sessions.2 The
study was brought to an end early because of a higher
rate of hospitalizations in the group randomly
assigned to higher average urea concentrations.
Overall mortality was low, with no difference in
mortality rates noted between the 2 urea concentration
groups. The association between allocation to a longer
dialysis treatment time and morbidity did not reach
statistical signiﬁcance (P 5 0.06), potentially reﬂecting limited statistical power.
After completion of the NCDS, the concept of Kt/V
emerged as the primary measure of hemodialysis adequacy.11 The deﬁnition of Kt/V is clearance of urea
multiplied by dialysis session duration divided by
volume of distribution of urea in the body, with
correction factors introduced for urea generation during dialysis and for volume and urea lost through ultraﬁltration. With the assumption that uremia reﬂects
the accumulation of organic waste products, mostly
524

small molecules that are normally cleared by the kidneys, this easily quantiﬁable measure of dialysis smallmolecule clearance supplanted clinical symptoms such
as hypertension and peripheral neuropathy as the
principal determinant of dialysis session duration.
Instead, hemodialysis adequacy was now predicated
on achieving a speciﬁed Kt/V or the simpler urea
reduction ratio.11 With the development of larger,
more efﬁcient, and less expensive hemodialysis
membranes, target Kt/Vs became readily achievable,
even in the setting of relatively short session lengths.
The HEMO Study evaluated whether higher target
Kt/V would be associated with better outcomes,
randomly assigning 1,846 patients receiving maintenance hemodialysis to either high- or standard-dose
dialysis and to a high- or low-ﬂux dialyzer using a
2 3 2 factorial design.3 The HEMO Study did not
speciﬁcally examine dialysis treatment time. Overall,
no signiﬁcant difference in mortality was noted
between the high-dose versus standard-dose group
(single-pool Kt/Vs of 1.65 and 1.25, respectively;
hazard ratio [HR], 0.96; 95% conﬁdence interval [CI],
0.84-1.10) or in the high-ﬂux versus low-ﬂux group
(HR, 0.92; 95% CI, 0.81-1.05).3
Shorter session length has advantages. For patients,
less time is required to be spent in the hemodialysis
facility; and for providers, more patients can be
treated in a ﬁxed time. Given that hemodialysis in the
United States is reimbursed based on the number of
treatment sessions without regard to duration of these
sessions, shorter session lengths may have substantial
economic beneﬁts for providers. Nevertheless, some
experts have recommended that hemodialysis session
duration should continue as a measurement of treatment adequacy.12

INITIAL CLINICAL GUIDELINES AND TREATMENT
TRENDS
The debate of hemodialysis time versus adequacy
assessed using urea nitrogen clearance (Kt/V or urea
reduction ratio) was discussed in the ﬁrst NKF-DOQI
guideline (“Hemodialysis and Peritoneal Dialysis
Adequacy and Vascular Access”) published in 1997.1
This initial guideline established the necessity of
measuring the dose (small-molecule clearance) of
dialysis in all long-term dialysis patients, but
consensus was not reached regarding the minimum
time for a dialysis treatment session.1 The 2006 NKFKDOQI guideline on dialysis adequacy suggested a
minimum of 3 hours of treatment time per session or 9
hours per week for patients with low (,2 mL/min)
residual kidney function, but also acknowledged the
lack of clinical trial data supporting any minimum
standard for dialysis session length.7 In contrast, the
European Best Practice Guidelines for Hemodialysis
published in 2002 stated that the standard minimum
Am J Kidney Dis. 2016;68(4):522-532
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hemodialysis dose should be delivered as three 4-hour
sessions per week and that session length and/or frequency should be extended in patients with hemodynamic instability.13 This statement was supported
by B level evidence, reﬂecting the limited clinical trial
data for hemodialysis session duration and patient
outcomes.
Potentially reﬂecting economic factors, patient
preferences, improved dialysis membranes, and the
clinical guidelines, the percentage of US patients with
session lengths less than 3 hours initially trended
downward from 37.2% in 1997 to 28.4% in 2006.
Interestingly, since 2006, the proportion of patients
with session lengths less than 3 hours has trended
upward, although overall average session length remains less than 4 hours (Fig 1).14 Although practice
patterns vary widely within the United States, clinical
data from the Dialysis Outcomes and Practice Patterns
Study (DOPPS) through 2011 reveal that average US
dialysis session lengths are lower than in all other
industrialized countries participating in the DOPPS
(Fig 1), with these lower session lengths posited as
one cause for higher mortality rates among US dialysis patients.15-17

Figure 1. (Top) Percentage of patients with session length
less than 3 hours and (bottom) average dialysis session length,
by year and by nation. Data for Sweden and Canada are not
available for 1999. Data from the Dialysis Outcomes and Practice Patterns Survey (www.dopps.org).

SESSION DURATION
By deﬁnition, higher IDWG and shorter dialysis
session length require higher UFRs to achieve any
desired postdialysis weight. Notably, higher UFRs
have been associated with increased mortality.17-19 In
a secondary analysis of the HEMO Study, the risk for
cardiovascular and all-cause mortality increased
sharply with UFRs between 10 and 14 mL/kg/h as
compared to UFRs , 10 mL/kg/h.18 Consequently,
in this analysis, UFR was stratiﬁed into #10, 10
to 13, and .13 mL/kg/h groups. Individuals with
UFRs . 13 mL/kg/h had a mean UFR of
16.8 6 3.6 (standard deviation) mL/kg/h and mean
IDWG of 3.6 6 1.0 L, whereas individuals with
UFRs # 10 mL/kg/h gained a mean of 2.1 6 10.9 L
between dialysis sessions. Average session length
differed signiﬁcantly among UFR groups: the .13mL/kg/h group, 209 minutes; 10- to 13-mL/kg/h
group, 220 minutes; and ,10-mL/kg/h group, 226
minutes (P , 0.001).
The highest UFR group in the HEMO Study had a
higher percentage of participants with heart failure
(44% vs 37% in the other groups). The presence of
heart failure at baseline in the HEMO Study modiﬁed
the association between UFR and mortality, such that
UFRs of 10 to 13 mL/kg/h were associated with
increased all-cause mortality and almost associated
with increased cardiovascular mortality in patients
with heart failure, but were not associated with mortality in patients without heart failure. UFR . 13 mL/
kg/h was associated with heightened mortality
regardless of heart failure status. Notably, the greater
risk for mortality associated with higher UFRs in the
HEMO Study was independent of IDWG, residual
urine output, and dialysis vintage. Although residual
kidney function could confound these results, only
one-third of HEMO Study participants had residual
urea clearance above zero, and mean dialysis vintage
among HEMO Study participants was 3.7 6 4.4
years.
These ﬁndings from the HEMO Study data are
supported by observations in an Italian cohort of adult
maintenance hemodialysis patients followed up for
approximately 4 years, in which mortality increased
linearly at UFRs . 12.4 mL/kg/h.19 Notably, all
observational studies showing an association between
higher UFRs and increased mortality risk are susceptible to residual confounding due to unmeasured variables. For example, patients with high IDWGs and
high UFRs may also have poor adherence to medications and dietary advice and/or poor social support,
factors that are difﬁcult to measure and may inﬂuence
mortality risk. In addition, the few studies showing an
association between UFRs and mortality risk relied on
observed UFR and not prescribed UFR.18,19
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The heightened mortality risk noted with higher
UFRs may be due to reductions in myocardial blood
ﬂow during hemodialysis sessions with large volume
removal.20,21 Repeated episodes of regional cardiac
ischemia can lead to myocardial ﬁbrosis, diastolic
dysfunction, and clinical heart failure22 and theoretically can heighten risk for arrhythmias and sudden
death.20,23-26 Serial echocardiograms in 30 patients
with a history of hemodialysis-induced myocardial
ischemia were performed to assess ﬁxed changes in
systolic dysfunction over time. After 12 months, 19
patients showed ﬁxed systolic function declines
. 60%.23 Assa et al27 completed echocardiograms
before a dialysis session, after 60 and 180 minutes of
a dialysis session, and then again at 30 minutes
postdialysis in 105 patients receiving maintenance
hemodialysis. Regional left ventricular systolic
dysfunction, deﬁned as an escalation in wall motion
scores in 2 or more segments, occurred in 27% of
patients, with most events occurring within 1 hour of
a dialysis session. However, in these observational
studies, UFRs did not differ among patients with and
without ﬁxed systolic function decline23 or regional
wall motion changes.27 Increasing the frequency or
duration of dialysis sessions and reducing the dialysate temperature along with biofeedback dialysis have
been shown to reduce the frequency of myocardial
stunning among patients receiving maintenance dialysis,28-30 but no study to date has demonstrated that
UFR limits mitigate reductions in myocardial perfusion or other cardiovascular outcomes during
hemodialysis.

UFR LIMITS AS A CLINICAL PERFORMANCE
MEASURE
The observation that high UFR may represent a risk
factor for patient mortality prompted the initial 2010
CMS Technical Expert Panel charged with establishing metrics for the ESRD Quality Improvement Program (QIP) to explore volume management measures
as a potential metric of dialysis quality.31 One
proposed metric emerging from this panel assessed
the proportion of patients with UFRs $ 15 mL/kg/h at
the treatment session when Kt/V was measured for the
reporting month, whereas others included documented
periodic assessment of dry weight and other process
measures. Although consensus was reached among
panel members, initial efforts to include ﬂuid management metrics in the QIP were unsuccessful due to
the lack of community-wide consensus regarding the
deﬁnition of ﬂuid overload, limited enthusiasm for
potential process measures such as updating the estimated dry weight, and concerns that the proposed
measure could not be readily manipulated.
In March 2013, the Chief Medical Ofﬁcer Initiative
convened the chief medical ofﬁcers of the 14 largest
526

US dialysis providers to meet and discuss ways to
improve clinical outcomes for dialysis patients. The
leaders participating in that meeting uniformly agreed
that despite its absence in any existing quality metric
at that time, optimizing extracellular ﬂuid status was a
critical element of dialysis care and that in many
ways, optimal volume control was equally important
to solute clearance in determining adequate dialysis.32
One key concordance from this initiative was that
ﬂuid removal should be gradual. Similarly, following
a modiﬁed Delphi process in which the kidney community was surveyed regarding the most important
element of dialysis care that remained unincorporated
in the QIP, Kidney Care Partners, a coalition of care
providers, nephrology professionals and professional
societies, manufacturers, and patient and patient
advocate groups that include the NKF,33 charged the
KCQA with developing a metric that addressed volume management in hemodialysis. Following review
of existing data and speciﬁcation testing using data
from 3 of the largest US dialysis providers, KCQA
developed and validated an ultraﬁltration metric that
assessed the percentage of patients receiving thriceweekly in-center hemodialysis with an average
UFR $ 13 mL/kg/h and session duration less than
240 minutes. This proposed measure incorporates
UFR and dialysis session duration for all 3 treatments
completed during the week of the monthly clearance
assessment. The KCQA-developed UFR measure was
endorsed by the National Quality Forum in 2015, but
to date has not been recommended by CMS as a
clinical performance measure for dialysis facilities.34
The potential use of UFR thresholds as a quality
metric recounts the 1997 NKF-DOQI hemodialysis
adequacy guideline that recommended avoidance of
excessive UFR and use of low UFRs for patients who
incur intradialytic hypotension and/or cramps. However, in that guideline, no ideal UFR was identiﬁed or
speciﬁed. Ultraﬁltration and IDWG were addressed
again in the 2006 NKF-KDOQI clinical practice
guideline for dialysis adequacy, with emphasis on the
importance of ﬂuid removal and treatment time.
Guideline 5 stated that the “ultraﬁltration component
of the hemodialysis prescription should be optimized
with a goal to render the patient euvolemic and
normotensive.”7 Poor volume control was recognized
as a major contributor to morbidity and mortality, but
no upper threshold for optimal UFR was identiﬁed.
This guideline discussed the variability in ultraﬁltration tolerance among patients and stated that a slow
approach to achieving dry weight was suitable for
most patients. However, the 2006 guideline also
suggested that patients with heart failure or severe
hypertension might require more aggressive ultraﬁltration and pointed out the lack of standards for
monitoring extracellular volume.7
Am J Kidney Dis. 2016;68(4):522-532
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The 2015 NKF-KDOQI guideline for dialysis adequacy emphasized a need to look beyond standard
measures of dialysis adequacy such as Kt/V in order
to determine whether dialysis was meeting the needs
of an individual patient. This guideline supported
previous recommendations for a 3-hour minimum
session length for patients with residual kidney
function ,2 mL/min, again without delineating a
speciﬁc UFR limit.4 It stated that the UFR for each
dialysis session should allow an optimal balance for
attaining euvolemia, blood pressure control, and solute clearance while also minimizing hemodynamic
instability and patient symptoms.4 The Renal Association, a professional society of nephrologists and
renal scientists in the United Kingdom, suggested
limiting UFR to 10 mL/kg/h based on the observation
that UFRs exceeding this threshold are associated
with higher morbidity and mortality.18 The Renal
Association also endorsed using the percentage of
patients with UFRs . 10 mL/kg/h as an audit measure for dialysis units.35

IMPLICATIONS OF A DIALYSIS FACILITY UFR
QUALITY MEASURE
Implementation of UFR limits will require
increased efforts for patients, clinicians, and staff,
with strong emphasis placed on reducing IDWG in
patients with high UFRs. A common practice for
controlling IDWG not supported by randomized
clinical trial data is instructing patients to limit ﬂuid
intake to , 1 L/d regardless of body weight. Given
the distribution of body water and the fact that high
sodium intake stimulates thirst, sodium restriction is
likely much more effective for limiting IDWG and
preventing volume overload.36,37 Unfortunately,
many patients receiving maintenance hemodialysis
live in poor communities with limited access to
nonprocessed healthy foods.
Dialysate sodium exposure may also be an area to
target for patients with volume overload and/or high
IDWG.36 The average dialysate sodium concentration
has increased from an approximate average of 135
mEq/L during the 1970s to 140 mEq/L today.38
Although higher dialysate sodium exposure minimizes changes in plasma osmolality during dialysis, it
may also increase IDWG.38-41 Intradialytic hypotension and cramping is sometimes addressed with sodium proﬁling, whereby the nephrologist prescribes a
supraphysiologic dialysate sodium concentration with
a gradual or stepwise decline in the dialysate sodium
concentration over the treatment session. Although
sodium modeling may improve plasma reﬁlling and
reduce risk for intradialytic hypotension and cramping, sodium proﬁling that leads to an overall net sodium gain may exacerbate thirst during the
intradialytic period and increase IDWG.42 Sodium

proﬁling may also be structured to achieve a neutral
sodium balance, with the postdialysis plasma sodium
level being equivalent to the predialysis plasma sodium level.42,43 When combined with ultraﬁltration
that decreases over the dialysis session length (ultraﬁltration proﬁling), sodium balance–neutral sodium
proﬁling decreases the risk for intradialytic hypotension while increasing the ability to achieve an ultraﬁltration goal in patients prone to intradialytic
hypotension.41,44,45 A personalized approach to sodium modeling may also be useful to reduce IDWG
by individualizing the dialysate sodium concentration
to the patient’s plasma sodium level.46,47 Although
existing trials addressing sodium-neutral sodium
modeling with and without ultraﬁltration modeling
and personalized sodium proﬁling demonstrate
beneﬁcial effects on IDWG, ultraﬁltration goals, and
blood pressure, 41,42,44-47 more and larger studies
representing the diverse demographics of the US
population are needed to determine optimal approaches for the dialysate composition to curtail
IDWG and help patients achieve a euvolemic state.
Additionally, more reliable measures of delivered
dialysate composition may be necessary to optimally
tailor dialysate sodium concentration to individual
patients.48 More studies are also needed to determine
best strategies for not only reducing sodium intake but
also for maintaining a reduced sodium intake. Such
studies should include a diverse dialysis population,
including patients with limited access to healthy
foods.
When strategies for mitigating high IDWG fail,
hemodialysis treatment time must be extended to
prevent a high UFR, and this may be accomplished by
increasing the duration or frequency of treatment
sessions. In a survey of 588 patients receiving maintenance hemodialysis in 18 dialysis units across the
United States, 44.6% of respondents were willing to
extend their session lengths by 15 minutes. However,
willingness to extend treatment time was dependent
on the liberalization of ﬂuid intake. Only 12.2% of
patients were willing to add a fourth treatment per
week, and only 13.5% were willing to accept
nocturnal dialysis.49 Increasing hemodialysis treatment time may also be constrained by the number of
hemodialysis shifts within an individual facility and
the number of available staff. Thus, the costs of
implementing UFR as a clinical performance measure
could include additional hemodialysis staff, reduction
in the total number of patients treated per day, and
additional use of water and other utilities. However,
the potential costs associated with UFR limitations as
a clinical performance measure remain unquantiﬁed.
Whether extending dialysis time affects outcomes
and quality of life is currently being addressed in the
Cluster-Randomized, Pragmatic Trial of Hemodialysis
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Session Duration (TiME; ClinicalTrials.gov study
number NCT02019225). TiME is evaluating whether a
minimum session length of 4.25 hours thrice weekly
versus usual care is associated with lower mortality,
fewer hospitalizations, and improved health-related
quality of life among incident hemodialysis patients.
This trial is a collaborative research effort between the
National Institutes of Health and 2 large dialysis
organizations in the United States: DaVita and
Fresenius Medical Care North America. The ACTIVE
(A Clinical Trial of Intensive) Dialysis Study
(ClinicalTrials.gov study number NCT00649298) is a
multicenter randomized trial of extending maintenance
hemodialysis treatment time to 24 hours per week or
longer versus the standard of 12 to 18 hours per week
for 12 months.50 Overall, 200 patients receiving
maintenance dialysis in Australia (29.0%), China
(62.0%), Canada (5.5%), and New Zealand (3.5%)
were enrolled, with the primary outcome being patient
quality of life. Secondary outcomes comprise change
in left ventricular mass index assessed by magnetic
resonance imaging and dialysis access events. The
ACTIVE Dialysis Study has been completed, but the
full results have not yet been published. Information
from TiME and the ACTIVE Dialysis Study may help
determine whether increasing dialysis treatment time
improves outcomes for patients receiving maintenance
hemodialysis.

DRY WEIGHT
Achieving a euvolemic state remains a primary
goal of hemodialysis treatments and is equated with
the achievement of a person’s dry weight. The deﬁnition of dry weight has changed over time. In 1967,
Thomson et al51 deﬁned dry weight as the weight at
which further ﬂuid removal leads to hypotension. The
1997 NKF-DOQI guideline strongly discouraged using hypotension at end of dialysis as an indicator of

estimated dry weight and discussed the impact of
intradialytic hypotension and cramps on an individual’s ability to complete hemodialysis treatments.1 However, more recent deﬁnitions state that
dry weight should be deﬁned as the lowest tolerated
postdialysis weight, with minimal hypovolemia
symptoms that can be achieved by a gradual change
in postdialysis weight.36,52 Although more studies are
needed, the Dry-Weight Reduction in Hypertensive
Hemodialysis Patients (DRIP) Study elegantly
demonstrated the importance of volume control to
achieve blood pressure control, including blood
pressure assessed outside of dialysis. The DRIP trial
also showed that quality of life did not differ between
patients with and without their dry weight probed.53
Focusing on UFR rates solely, rather than achievement of a euvolemic state, ignores the fact that some
patients who are volume overloaded do not have high
IDWG.36,38,54 In this regard, the lack of a gold standard to reliably assess dry weight remains a major
impediment to achieving a euvolemic state in patients
receiving maintenance hemodialysis.32
Table 2 lists potential methods for assessing
extracellular volume to manage ultraﬁltration needs.
No current method can accurately pinpoint an individual patient’s dry weight, and the majority of clinicians rely on physical examination ﬁndings, which
are highly insensitive for detection of a volumeoverloaded state.55-57 Existing studies suggest that
bioimpedance, lung ultrasonography, and relative
plasma volume monitoring can help guide ultraﬁltration goals and improve overall volume status and
blood pressure.58-62 Inferior vena cava diameter
measures show measurable and consistent change in
response to probing dry weight among patients
receiving maintenance dialysis. However, the change
in inferior vena cava diameter does not correlate with
blood pressure responses to reductions in postdialysis

Table 2. Current Methods for Assessing Extracellular Volume in Patients Receiving Maintenance Hemodialysis
Indicator

Pros

Physical examination
Postdialysis hypotension

No equipment needed
No equipment needed

Bioimpedance

Available, validated in many
different patient populations
Available

Vena cava diameter

Brain natriuretic peptide
Blood volume monitoring
Lung ultrasound

528

High plasma levels associated
with volume overload
Low intraindividual variability
Detection of pulmonary
congestion predicts mortality

Cons

References

Low sensitivity
Increased mortality risks, cramping, early dialysis
termination
Requires equipment, cost, training
Requires equipment, cost, training; may be
operator dependent; lack of normative data for
patient size
Influenced by cardiac disease, intradialytic removal,
and fistula blood flow
Lack of standards to predict hypotension, not widely
available
Requires equipment and training; clinical trials
ongoing; mainly sensitive for volume overload
and not for determining dry weight

55-57
76-78
58-60, 79, 80
63, 81, 82

83, 84
62, 85
58, 74
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weight.63 Larger studies of diverse populations are
needed to determine the optimal measure of extracellular ﬂuid status and the best method for implementing extracellular ﬂuid status measures in clinical
practice for the prevention of high UFRs and
achieving euvolemic states in patients receiving
maintenance dialysis.

VOLUME OVERLOAD, HYPERTENSION, AND
HEART FAILURE
Although controversy surrounds the optimal blood
pressure targets for patients receiving maintenance
hemodialysis,64,65 maintaining interdialytic blood
pressure at ,140/90 mm Hg has been suggested as a
reasonable goal for patients receiving maintenance
hemodialysis.66 Because blood pressure control
among most patients receiving maintenance hemodialysis is largely volume dependent,67,68 achieving this
blood pressure goal requires more aggressive ultraﬁltration for many patients.69 However, if a shortterm UFR threshold impedes the ability to obtain a
euvolemic state in patients with high IDWG, ﬂuid
overload and blood pressure increase, requiring a
higher number of antihypertension medications. This
polypharmacy may have important consequences,
including cost and drug-drug interactions.
Long-term volume overload also increases the risk
for heart failure and mortality.70-72 Heart failure and
ﬂuid overload are among the most common reasons
for hospitalization among maintenance hemodialysis
patients. Arneson et al73 analyzed the total cost of
hospitalization care for volume overload in 176,790
patients receiving maintenance hemodialysis over an
average of 2 years. Among the 25,291 patients with
claims data meeting criteria for volume overload, the
total cost for hospitalizations and emergency department care during this period exceeded US $260
million.73 Volume overload is also associated with
heightened risk for mortality. Among 269 hemodialysis patients with an average dialysis vintage of 41.2
months, a 2.5-L extracellular water excess assessed by
body composition monitor was associated with a 2fold higher mortality rate over a 3.5-year followup.71 Similarly, using lung ultrasound, Zoccali et al74
showed that very severe pulmonary congestion was
associated with a 4.2-fold higher (95% CI, 2.45-7.23)
risk for death among 392 patients receiving maintenance hemodialysis in Italy. Aside from heart failure
and hypertension, long-term volume overload may
also impair pulmonary function and increase the risk
for pulmonary hypertension, a condition that may go
unrecognized in many patients and that is associated
with high mortality risk.75
Critically, an ultraﬁltration metric cannot exist in
isolation, but rather would be considered as
one metric among many that are applied to dialysis

facilities, and the interplay among these metrics could
provide important information. For example, if in
striving to meet an ultraﬁltration threshold, patients
have more cramping or are compelled to undergo
longer hemodialysis sessions, their satisfaction with
the dialysis facility may decrease, resulting in lower
In-Center Hemodialysis Consumer Assessment of
Healthcare Providers and Systems (ICH CAHPS)
scores. In contrast, if facilities increase the estimated
dry weight to meet an ultraﬁltration threshold, volume
overload may occur more often, resulting in increased
deaths, hospitalizations, and hospital readmissions.
Nonclinical issues should also be considered before
implementing a UFR limitation as a clinical performance measure. First, the current UFR measure suggested by the KCQA indexes UFR to body weight.
Patients with lower body weight will have a higher
UFR for a given IDWG compared with larger patients. Use of one UFR threshold for all patients
regardless of body size will differentially affect hemodialysis units. Units with a large percentage of
patients with low body weight, such as older women,
frail and elderly patients, and patients with Asian or
Hispanic background, will likely have a higher percentage of UFRs . 13 mL/kg/h and session lengths
less than 240 minutes compared with units with a
high percentage of young and male patients. Second,
UFR depends on IDWG, which is highly variable
across time. For example, UFRs are typically highest
at the ﬁrst dialysis session of the week due to the long
weekend; IDWG is also affected by season, holiday,
and other family celebrations that occur throughout a
year. Averaging the UFR over the week that Kt/V is
reported may not allow ﬂexibility for the inherent
variability in patient IDWG. It also remains unknown
whether UFR limits should be based on ideal, actual,
or dry body weight. Tolerance of a given UFR in a
lean and muscular 90-kg individual is likely to be
different from one of the same weight with a much
higher percentage of body fat and/or edema.
In summary, the unique payment structure for
dialysis treatment in the United States has led to
shorter dialysis session lengths requiring high UFRs
in patients with large IDWGs. High UFRs are associated with increased mortality, and limiting UFRs
has been proposed as a way to improve patient outcomes. If not properly implemented, it is also possible
that a policy establishing a UFR limit could increase
the risk for unintended consequences, including
complications related to long-term volume overload
such as increased blood pressure and heart failure. For
many patients, increasing hemodialysis session length
or adding additional sessions will be required to avoid
high UFRs, an unpalatable prospect for many patients. Box 1 lists the research recommendations to
enhance support for use of a UFR limitation as a
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Box 1. Research Recommendations for UFR Thresholds as a
Clinical Performance Measure
1. Identify optimal measures for assessing extracellular
volume in patients receiving maintenance hemodialysis.
2. Develop effective methods to modify behaviors for
reducing intradialytic weight gain and salt intake.
3. Determine the impact of implementing UFR
limits (eg, $13 mL/kg/h) on hospital admissions, readmissions, and mortality.
4. Quantify the impact of UFR limits (eg, $13 mL/kg/h) on
blood pressure, blood pressure control, and number of
antihypertension medications prescribed for patients
receiving maintenance hemodialysis.
5. Determine whether indexing the UFR for measures such
as body surface area or body mass index influences the
association between UFR and patient outcomes.
6. Establish whether patients are willing to extend dialysis
time to maintain UFRs , 13 mL/kg/h.
7. Examine whether the association between UFR and
patient outcome differs by residual kidney function and
whether UFR limits (eg, $13 mL/kg/h) affect loss of residual kidney function over time.
8. Quantify the financial impact of implementing UFR
thresholds on hemodialysis units.
9. Determine appropriate risk adjusters and performance
thresholds consistent with high-quality care based on a
metric defining UFR limits (eg, $13 mL/kg/h).
10. Examine use of sodium profiling with and without ultrafiltration profiling for prevention of intradialytic hypotension, interdialytic weight gain, and patient outcomes.
11. Investigate the role of extracellular fluid status measures
for determining UFR goals and achievement of dry
weight and blood pressure goals.
12. Determine the optimal dialysate concentrations that
minimize interdialytic weight gain, hospitalization rates,
and mortality.
Abbreviation: UFR, ultrafiltration rate.

clinical performance measure. Currently, few studies
have examined the effectiveness of behavioral modiﬁcation programs and dialysate concentrations to
minimize IDWG. With thrice-weekly hemodialysis,
achievement and maintenance of a near-euvolemic
state remains one of the most important and challenging goals. More studies are also needed to identify accurate and reliable methods to determine the
extracellular volume status of a patient receiving
maintenance hemodialysis and how these measures
can be implemented into practice to optimize patient
quality of life and overall survival. Identifying these
gaps in knowledge may greatly improve the care of
patients receiving maintenance hemodialysis and will
help delineate the clinical implications of a UFR
limitation as a clinical performance measure.
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